Nishadil
Signup Signin
Delhi | 25°C (windy)
The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance
Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market

Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market
Mpox in Africa: A Grave, Enduring Health Emergency Declared by WHO

Mpox in Africa: A Grave, Enduring Health Emergency Declared by WHO
The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?
Halozyme gains as U.S. and EU clear Enhanze based products

Halozyme gains as U.S. and EU clear Enhanze based products
Load more..